Ultragenyx Pharma (RARE.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec11

Ultragenyx CFO Reports Sale of Company Shares

17:12

Nov16

Ultragenyx Secures $400 Million Non-Dilutive Financing and Expands Crysvita Royalties

22:02

Nov5

Morgan Stanley Reiterates Buy Rating on Ultragenyx Pharmaceutical

17:21

Werber Reiterates Hold Rating on Ultragenyx Pharmaceutical

12:02

Ultragenyx Pharma released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 159.93 M (forecast USD 166.79 M), actual EPS USD -1.81 (forecast USD -1.2377)

00:00

Ultragenyx Pharma released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 465.72 M and EPS of USD -4.5447

00:00

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 159.93 M, Net Income -180.41 M, EPS -1.8082

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 166.5 M, Net Income -114.95 M, EPS -1.1674

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 139.29 M, Net Income -151.08 M, EPS -1.569

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change